Clinical characteristics | High-eIF4A1 | Low-eIF4A1 | P-value |
---|---|---|---|
Age, mean ± SD, years | 66.04 ± 9.69 | 64.10 ± 10.07 | 0.482 |
Male, n (%) | 13 (56.53%) | 21 (70.00%) | 0.311 |
Overall survival, median, months | 6.0 (4.0, 9.0) | 9.0 (8.0, 15.5) | 0.006b |
Differentiation status | Â | 0.523 | |
 Well differentiated | 11 (20.75%) | 17 (32.08%) |  |
 Moderately to poorly differentiated | 12 (22.64%) | 13 (24.53%) | |
Tumor size, mean ± SD, cm | 4.57 ± 1.40 | 3.75 ± 1.28 | 0.032b |
Recurrences, n (%) | 17 (73.91%) | 20 (66.67%) | 0.569 |
Location | Â | 0.267 | |
 Head, n (%) | 15 (28.30%) | 18 (33.96%) |  |
 Body/tail, n (%) | 7 (13.21%) | 20 (37.74%) | |
Diffusion involvement, n (%) | 1 (1.89%) | 2 (3.77%) | |
TNM stagea | Â | 0.077 | |
 I–II stage, n (%) | 14 | 24 |  |
 III–IV stage, n (%) | 9 | 5 | |
Lymph node metastasis, n (%) | 14 (63.64%) | 10 (35.71%) | 0.0498* |
Vascular Infiltration, n (%) | 10 (43.48%) | 3 (10.00%) | 0.272 |